PMID- 30650476
OWN - NLM
STAT- MEDLINE
DCOM- 20190221
LR  - 20190221
IS  - 1003-5370 (Print)
IS  - 1003-5370 (Linking)
VI  - 37
IP  - 3
DP  - 2017 Mar
TI  - [A Systematic Review on Safety Evaluation of Treating Cardiovascular Diseases by 
      Shuxuening In- jection].
PG  - 283-290
AB  - Objective To systematically evaluate the safety of Shuxuening Injection ( SI) for 
      treating cardiovascular disease in line with indications. Methods Ten databases 
      such as Cochrane Li- brary, Medline, EMBase, Web of Science, Clinical Trials, 
      CBM, CNKI, VIP, Wangfang Data, and Chinese Clinical Trial Registry Database were 
      retrieved in October 2015 for collecting literatures on use of SI. Data were 
      screened by inclusion and exclusion criteria. Literatures retrieved included 
      randomized controlled trials, non-randomized controlled trials, observational 
      research (case control, cohort studies, case series, case reports, and so on) , 
      and were methodologically evaluated by Cochrane Systematic Risk of Bias Manual, 
      TREND, and SUMARI. Results A total of 185 literatures were retrieved in this 
      systematic review. Of them, 155 randomized controlled trials( RCT) , 6 
      non-randomized controlled trials, 11 case series, and 13 case reports were 
      finally identified. Among the 13 case reports, adverse drug reactions (ADRs) 
      occurred in 15 cases. Of the 155 RCT studies, XI was used in 8 553 patients, with 
      ADRs in 162 cases and adverse events (AEs) in 4 cases. The outcomes of ADRs 
      mainly covered the gastrointestinal system damage, central/peripheral nervous 
      system damage, skin and appendages injury, and so on. The degree of damage was 
      mostly mild. It is difficult to get a clear judgment on the relationship be- 
      tween the occurrence of these ADRs and drug dosage, drug administration, drug 
      solvents, and combina- tion medications. Conclusions The general safety of using 
      XI for treating cardiovascular diseases was acceptable in this systematic review. 
      Although Xl was systematically analyzed to be safely used in case reports, 
      mechanism studies or large sample observational studies are lack.
FAU - Chen, Hong-Yu
AU  - Chen HY
FAU - Xie, Yan-Ming
AU  - Xie YM
FAU - Liao, Xing
AU  - Liao X
FAU - Chen, Yuan-Yuan
AU  - Chen YY
LA  - chi
PT  - Journal Article
PT  - Systematic Review
PL  - China
TA  - Zhongguo Zhong Xi Yi Jie He Za Zhi
JT  - Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese 
      journal of integrated traditional and Western medicine
JID - 9211576
RN  - 0 (Drugs, Chinese Herbal)
RN  - 0 (shuxuening)
SB  - IM
MH  - *Cardiovascular Diseases/drug therapy
MH  - *Drug-Related Side Effects and Adverse Reactions
MH  - *Drugs, Chinese Herbal/adverse effects/therapeutic use
MH  - Humans
MH  - Injections
MH  - Randomized Controlled Trials as Topic
EDAT- 2017/03/01 00:00
MHDA- 2017/03/01 00:01
CRDT- 2019/01/17 06:00
PHST- 2019/01/17 06:00 [entrez]
PHST- 2017/03/01 00:00 [pubmed]
PHST- 2017/03/01 00:01 [medline]
PST - ppublish
SO  - Zhongguo Zhong Xi Yi Jie He Za Zhi. 2017 Mar;37(3):283-290.